Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 114

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 114
---
’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

J. RESEARCH AND DEVELOPMENT COST

Research and development (R&D) costs are expensed as incurred. R&D costs are related to the Company’s internally funded development of the Company’s product developments and patents. The Company R&D costs were $0 and $47,528 for the quarters ended December 31, 2024 and 2023.

K. FAIR VALUE MEASUREMENT

The estimated fair values of financial instruments reported in the consolidated financial statements have been determined using available market information and valuation methodologies, as applicable. The fair value of cash due to its short maturity is classified as a Level 1instrument within the fair value hierarchy.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Entities are required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value based upon the following fair value hierarchy:

Level 1 — Quoted prices in active markets for identical assets or liabilities;

Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

As of December 31 , 2024,the following table represents the Company’s fair value hierarchy for items that are required to be measured at fair value on a recurring basis:

|                            |     | Level 
 1     |     | Level 
 2     |     | Level 
 3     |        |
|:---------------------------|:----|:------|:----|:------|:----|:------|-------:|
| Investment                 
 Securities (Related Party) |     |       |     |       |     | $     | 17,733 |

As of September 30, 2024,the following table represents the